176 related articles for article (PubMed ID: 27747005)
41. Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.
Wojcik E; Kulpa JK
Lung Cancer (Auckl); 2017; 8():231-240. PubMed ID: 29238236
[TBL] [Abstract][Full Text] [Related]
42. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS.
Torsetnes SB; Levernæs MS; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Chem; 2014 Jul; 86(14):6983-92. PubMed ID: 24945626
[TBL] [Abstract][Full Text] [Related]
43. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
44. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
45. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
WANG J; GAO J; HE J
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
[TBL] [Abstract][Full Text] [Related]
46. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
47. Preliminary radioimmunoimaging and biodistribution of ¹³¹iodine-labeled single-chain antibody fragment against progastrin-releasing peptide(₃₁₋₉₈) in small cell lung cancer xenografts.
Hong Z; Shi Y; Liu Z; Zhou X; Yang Y; Tang J
Chin Med J (Engl); 2014; 127(11):2007-11. PubMed ID: 24890142
[TBL] [Abstract][Full Text] [Related]
48. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
Miyake Y; Kodama T; Yamaguchi K
Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
[TBL] [Abstract][Full Text] [Related]
49. Progastrin-releasing peptide: stability in plasma/serum and upper reference limit.
Nordlund MS; Bjerner J; Warren DJ; Nustad K; Paus E
Tumour Biol; 2008; 29(3):204-10. PubMed ID: 18667845
[TBL] [Abstract][Full Text] [Related]
50. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
51. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.
Korse CM; Taal BG; Bonfrer JMG; Vincent A; van Velthuysen ML; Baas P
Ann Oncol; 2011 Dec; 22(12):2625-2630. PubMed ID: 21415235
[TBL] [Abstract][Full Text] [Related]
52. Elevated progastrin-releasing peptide(31-98) concentrations in pleural effusions due to small-cell lung carcinoma.
Shijubo N; Hirasawa M; Sasaki H; Igarashi T; Fujita A; Kodama T; Yamaguchi K; Abe S
Respiration; 1996; 63(2):106-10. PubMed ID: 8966363
[TBL] [Abstract][Full Text] [Related]
53. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
Huang Z; Xu D; Zhang F; Ying Y; Song L
Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
[TBL] [Abstract][Full Text] [Related]
54. Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer.
Lv ShP; Wang Y; Huang L; Wang F; Zhou JG; Ma H
Asian Pac J Cancer Prev; 2017 Feb; 18(2):391-397. PubMed ID: 28345820
[TBL] [Abstract][Full Text] [Related]
55. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
56. Characteristics and clinical validity of two immunoassays for ProGRP.
Nordlund MS; Stieber P; Brustugun OT; Warren DJ; Paus E
Tumour Biol; 2012 Aug; 33(4):1105-13. PubMed ID: 22399443
[TBL] [Abstract][Full Text] [Related]
57. Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients.
Li L; Yin X; Meng H; Hu J; Yu Z; Xu J
Yonsei Med J; 2020 Jan; 61(1):15-19. PubMed ID: 31887795
[TBL] [Abstract][Full Text] [Related]
58. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
59. ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment.
Kato Y; Tanaka Y; Hino M; Gemma A
Respir Med Case Rep; 2019; 27():100837. PubMed ID: 31016132
[TBL] [Abstract][Full Text] [Related]
60. High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO₂-Au Nanocomposite.
Wei Z; Cai X; Zhang J; Fan J; Xu J; Xu L
Molecules; 2019 Feb; 24(4):. PubMed ID: 30781735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]